Rapamycin inhibits the proliferation and apoptosis of gastric cancer cells by down regulating the expression of survivin

Hepato-Gastroenterology

Volumn 58, Issue 107-108, 2011, Pages 1075-1080

  Yao, Chun ^a   Liu, Jinxiu ^a   Shao, Liwei ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Gastric cancer; mTOR; Rapamycin; Survivin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; RAPAMYCIN; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM INVASIVENESS; SIROLIMUS; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 80051616678     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Yaghoobi M, Bijarchi R, Narod SA: Family history and the risk of gastric cancer. Br J Cancer 2010; 102(2):237-42.
2. Li W, Zeng J, Li Q, et al.: Reptin is required for the transcription of telomerase reverse transcriptase and over-expressed in gastric cancer. Mol Cancer 2010; 9:132.
3. Enzinger PC, Benedetti JK, Meyerhardt JA, et al.: Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg 2007; 245(3):426-34.
4. Junnila S, Kokkola A, Karjalainen-Lindsberg ML, et al.: Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer 2010; 10:73.
5. Tetzlaff ED, Cheng JD, Ajani JA: Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag 2008; 4(5):999-1007.
6. Park S, Chapuis N, Tamburini J, et al.: Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2010; 95(5):819-28.
7. Treeck O, Wackwitz B, Haus U, et al.: Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006; 102(2):292-9. (Pubitemid 44041641)
8. Brachmann SM, Hofmann I, Schnell C, et al.: Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA. 2009; 106(52):22299-304.
9. Gazitt Y, Kolaparthi V, Moncada K, et al.: Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Int J Oncol 2009; 34(2):551-61.
10. Memmott RM, Dennis PA: The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res 2010; 16(1):4-10.
11. Park S, Chapuis N, Tamburini J, et al.: Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2010; 95(5):819-28.
12. Albert L, Karsy M, Murali R, et al.: Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme. Cancer Genomics Proteomics 2009; 6(5):255-61.
13. Di Cosimo S: Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy. Breast Cancer Res 2009; 11Suppl3:S25.
14. Mita AC, Mita MM, Nawrocki ST, et al.: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14(16):5000-5.
15. Wu YF, Liang XJ, Liu YY, et al.: Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63. Neoplasma 2010; 57(6):501-6.
16. Kinoshita J, Fushida S, Harada S, et al.: Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int J Oncol 2009; 34(6):1573-82.
17. Montorsi M, Maggioni M, Falleni M, et al.: Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 2007; 54(79):2040-4.
18. Ozdemir NY, Abali H, Oksüzodlu B, et al.: The efficacy and safety of reduced-dose docetaxel, cisplatin and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol 2010; 27(3):680-4.
19. Cho YG, Song JH, Kim CJ, et al.: Genetic alterations of the ATBF1 gene in gastric cancer. Clin Cancer Res 2007; 13(15 Pt 1):4355-9.
20. Ma XM, Yu H, Huai N: Peroxisome proliferator-activated receptor-gamma is essential in the pathogenesis of gastric carcinoma. World J Gastroenterol 2009; 15(31):3874-83.
21. Kim DY, Cha ST, Ahn DH, et al.: STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol 2009; 24(4):646-51.
22. Fukata M, Abreu MT: Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 2008; 27(2):234-43.
23. Generali D, Fox SB, Brizzi MP, et al.: Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 2008; 14(9):2673-80.
24. Sparks CA, Guertin DA: Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010; 29(26):3733-44.
25. Jimenez RH, Boylan JM, Lee JS, et al.: Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines. PLoS One 2009; 4(10):e7373.
26. Villanueva A, Chiang DY, Newell P, et al.: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135(6):1972-83.
27. Sun YW, Huang WJ, Hsiao CJ, et al.: Methoxychalcone induces cell-cycle arrest and apoptosis in human hormone-resistant prostate cancer cells through PI 3-kinase-independent inhibition of mTOR pathways. Prostate 2010; 70(12):1295-306.
28. Xiao L, Wang YC, Li WS, et al.: The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res 2009; 28:152.
29. Gurbuxani S, Xu Y, Keerthivasan G, et al.: Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci USA: 2005; 102(32):11480-5. (Pubitemid 41153845)
30. Liang X, Da M, Zhuang Z, et al.: Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro. Cell Biol Int 2009; 33(1):119-24.
31. Wang YH, Chiou HY, Lin CT, et al.: Association between survivin gene promoter -31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 2009; 73(3):670-4.
32. Adamkov M, Halasova E, Kajo K, et al.: Survivin: a promising biomarker in breast carcinoma. Neoplasma 2010; 57(6):572-7.